Like any medication, GLP-1s aren't without risks
They bind to the same receptors and produce similar outcomes: increased insulin release reduced appetite slower gastric emptying improved blood-sugar control For people with severe insulin resistance or poorly controlled diabetes, these medications can be extremely helpful in the short term
A few key players are AstraZeneca, Boehringer Ingelheim, D&D Pharmatech, Eli Lilly, Hanmi Pharmaceutical, Novo Nordisk, Pfizer, Roche, Sanofi, and Tonghua Dongbao Pharmaceutical
Clinical and Translational Implications These findings illuminate a novel IGF-1mediated immunosuppressive axis that may underlie the refractory nature of prostate cancer to PD-1/PD-L1 blockade
1 IU is the organic equivalent of 0.025 mcg